Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for the treatment of transthyretin-mediated (ATTR)
Latest Ratings for ALNY
DateFirmActionFromTo Mar 2022CitigroupInitiates Coverage OnBuy Feb 2022Morgan StanleyMaintainsOverweight Feb 2022SVB LeerinkMaintainsMarket Perform
